<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996720</url>
  </required_header>
  <id_info>
    <org_study_id>fdpicu-04</org_study_id>
    <nct_id>NCT03996720</nct_id>
  </id_info>
  <brief_title>Early Identification and Effective Management of Pediatric Sepsis</brief_title>
  <official_title>Integration of Metabolic and Inflammatory Mediator Profiles as a Potential Diagnostic Approach for Severe Sepsis in PICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients diagnosed as sepsis on PICU admission, early and accurate identification of
      patients who will develop organ dysfunction (severe sepsis) is critical for effective
      management and positive outcome. A multiple marker approach would improve clinical utility
      compared with use of a single marker. The primary goal of this part of study is to define a
      combination of multiple markers, derived from novel biomarkers (nCD-64, IL-27, sTREM, HLA-DR,
      IL-10), metabolomics and routine clinical parameters, which could predict severe sepsis and
      determine the severity of disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We intend to enroll pediatric sepsis patients at four PICUs and divide them into two groups
      based on clinical outcomes: severe sepsis group (patients who progress into severe sepsis),
      sepsis group (patients who do not progress in to severe sepsis). We intend to perform
      predictive modeling using multivariable analyses of the novel biomarkers and derive a
      biomarker panel and algorithm for early diagnosis of severe sepsis. The predictive value of
      the biomarker panel for early identification of severe sepsis will be compared with
      established indices, such as PRISM III and pSOFA score.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>Severe sepsis</measure>
    <time_frame>28 day</time_frame>
    <description>Sepsis plus one of the following: cardiovascular organ dysfunction OR acute respiratory distress syndrome OR two or more other organ dysfunctions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>28 day</time_frame>
    <description>death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>secondary infection</measure>
    <time_frame>28 day</time_frame>
    <description>infection acquired 48h after PICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of ICU stay</measure>
    <time_frame>28 day</time_frame>
    <description>from PICU admission to discharge</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>severe sepsis</arm_group_label>
    <description>patients who diagnosed as sepsis upon PICU admission and develop organ dysfunction during PICU stay</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sepsis</arm_group_label>
    <description>patients recover from sepsis without developing into organ dysfunction</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      2ml of whole blood collected in sterile tubes containing EDTA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with sepsis from four tertiary PICUs in Shanghai
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The presence of at least two of the following four criteria, one of which must be
             abnormal temperature or leukocyte count:

               -  Coreb temperature of &gt;38.5°C or &lt;36°C.

               -  Tachycardia, defined as a mean heart rate &gt;2 SD above normal for age in the
                  absence of external stimulus, chronic drugs, or painful stimuli; or otherwise
                  unexplained persistent elevation over a 0.5- to 4-hr time period OR for children
                  &lt;1 yr old: bradycardia, defined as a mean heart rate &lt;10th percentile for age in
                  the absence of external vagal stimulus, β-blocker drugs, or congenital heart
                  disease; or otherwise unexplained persistent depression over a 0.5-hr time
                  period.

               -  Mean respiratory rate &gt;2 SD above normal for age or mechanical ventilation for an
                  acute process not related to underlying neuromuscular disease or the receipt of
                  general anesthesia.

               -  Leukocyte count elevated or depressed for age (not secondary to
                  chemotherapy-induced leukopenia) or &gt;10% immature neutrophils

          -  A suspected or proven (by positive culture, tissue stain, or polymerase chain reaction
             test) infection caused by any pathogen OR a clinical syndrome associated with a high
             probability of infection. Evidence of infection includes positive findings on clinical
             exam, imaging, or laboratory tests

        Exclusion Criteria:

          -  patients without informed consent

          -  discharge within 48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Guoping Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guoping Lu, MD</last_name>
    <phone>13788904150</phone>
    <email>13788904150@i63.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chunying Peng</last_name>
    <phone>18258827399</phone>
    <email>pengchunying@icloud.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yucai Zhang, MD</last_name>
      <phone>18917128301</phone>
      <email>zhangyc@shchildren.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Medical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Wang, MD</last_name>
      <phone>18930830600</phone>
      <email>ywangpicu@shsmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Zhu, MD</last_name>
      <phone>13651727806</phone>
      <email>zhuxiaodong@xinhuamed.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolomics</keyword>
  <keyword>biomarkers</keyword>
  <keyword>inflammatory mediator profile</keyword>
  <keyword>MODS</keyword>
  <keyword>predictive model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

